Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 54Breast Neoplasms 43Neoplasms 4Salivary Gland Neoplasms 3Triple Negative Breast Neoplasms 2Prostate Adenocarcinoma 2Advanced Breast Cancer 2Recurrence 1PSA Level Greater Than Two 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphatic Metastasis 1Inflammatory Breast Neoplasms 1Hormone-sensitive Metastatic Breast Cancer 1Hormone Sensitive Prostate Cancer 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1HER2 Negative Breast Cancer 1Fallopian Tube Neoplasms 1Castrate Sensitive Prostate Cancer 1Carcinoma, Ovarian Epithelial 1Carcinoma, Lobular 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms, Male 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

bicalutamide 4pembrolizumab 1nilutamide 1exemestane 1darolutamide 1cabazitaxel 1apalutamide 1abemaciclib 1Vorinostat 1Triptorelin Pamoate 1Tamoxifen 1Letrozole 1Histamine H2 Antagonists 1Histamine Antagonists 1Goserelin 1Doxorubicin 1Dasatinib 1Cisplatin 1CP protocol 1Aromatase Inhibitors 1Antiemetics 1Anastrozole 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bulbo-Spinal Atrophy, X-Linked × Goserelin × Clear all
NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

National Cancer Center Hospital East

Phase 2 Completed
57 enrolled
Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡